Stockscreener 앱 받기
0.7482
2.76%
0.0171
전일 마감가:
$0.7311
열려 있는:
$0.7313
하루 거래량:
9,828
Relative Volume:
0.00
시가총액:
$8.43M
수익:
$488.20K
순이익/손실:
$-13.04M
주가수익비율:
-0.3495
EPS:
-2.141
순현금흐름:
$-13.57M
1주 성능:
-1.79%
1개월 성능:
-8.14%
6개월 성능:
-47.83%
1년 성능:
-68.17%
1일 변동 폭
$0.7313
$0.7597
1주일 범위
$0.72
$0.84
52주 변동 폭
$0.548
$2.65
Aprea Therapeutics Inc Stock (APRE) Company Profile
명칭
Aprea Therapeutics Inc
전화
215-948-4119
주소
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.7365 | 8.37M | 488.20K | -13.04M | -13.57M | -2.141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.54 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.00 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
680.44 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.02 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
281.47 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-06-22 | 개시 | H.C. Wainwright | Neutral |
| 2020-04-21 | 개시 | Robert W. Baird | Outperform |
| 2019-10-28 | 개시 | JP Morgan | Neutral |
| 2019-10-28 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-10-28 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
Aprea Therapeutics (APRE) files amendment adding EisnerAmper consent to registration - Stock Titan
Aprea Therapeutics (APRE) Projected to Post Quarterly Earnings on Tuesday - Defense World
Aprea Therapeutics (NASDAQ: APRE) CEO receives new equity awards - Stock Titan
Equity awards lift Aprea (NASDAQ: APRE) CFO Hamill’s share stake - Stock Titan
H.C. Wainwright Maintains Buy on APRE Aprea Therapeutics Inc March 2026 - Meyka
Aprea Therapeutics Reports 2025 Financial Results and Clinical Progress for APR-1051 WEE1 Inhibitor in Endometrial Cancer - Minichart
H.C. Wainwright reiterates Aprea stock rating, keeps $4 target - Investing.com
Aprea reports second partial response in phase 1 APR-1051 trial - MSN
Aprea Highlights Early APR-1051 Data and Financial Update - TipRanks
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - Bitget
Aprea Therapeutics Q4 eps usd -0.32 - marketscreener.com
[10-K] Aprea Therapeutics, Inc. Files Annual Report | APRE SEC FilingForm 10-K - Stock Titan
Aprea Therapeutics 10-K: $0.286M Grant Revenue, Loss per Share $(1.93) - TradingView
APRE: Clinical progress and improved financials position the company for key milestones in 2026 - TradingView
Aprea Therapeutics (Nasdaq: APRE) posts 2025 loss and oncology pipeline update - Stock Titan
Aprea Therapeutics Q4 EPS $(0.32) Misses $(0.... - Benzinga
Aprea Therapeutics Q4 net loss narrows as R&D costs fall - TradingView
Experimental endometrial cancer drug cut tumors by half in 2 patients - Stock Titan
Plus: Q4 Earnings Snapshot - Barchart.com
APRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aprea Therapeutics stock rises after company reports second unconfirmed case of tumor reduction in trial - MSN
Published on: 2026-03-07 13:05:37 - baoquankhu1.vn
Stock Report: Is Aprea Therapeutics Inc backed by strong institutional buyingJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051 - Barchart.com
Aprea Reports Second Partial Response in Phase 1 APR-1051 Trial - MyChesCo
Aprea to Present at Oppenheimer Healthcare Conference - MyChesCo
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Aprea Therapeutics (NASDAQ:APRE) Upgraded at Zacks Research - Defense World
Aprea reports second partial response in endometrial cancer trial - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Aprea Therapeutics announces additional positive clinical activity for Wee1 inhibitor, APR-1051 - marketscreener.com
Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051 - TradingView
Aprea Highlights Encouraging Phase 1 Data for APR-1051 - TipRanks
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial - The Manila Times
Experimental cancer drug shrinks endometrial tumor by 50% in early trial - Stock Titan
Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - VISTA.Today
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
APREAprea Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
IPO Launch: Is Aprea Therapeutics Inc gaining market shareWeekly Market Summary & Daily Profit Maximizing Tips - baoquankhu1.vn
Will Aprea Therapeutics Inc. stock hit new highs in YEARQuarterly Trade Summary & Weekly High Return Forecasts - mfd.ru
Is Aprea Therapeutics Inc. a potential multi baggerJuly 2025 Rallies & Expert-Curated Trade Recommendations - mfd.ru
Will Aprea Therapeutics Inc. stock go up in YEARJuly 2025 Sentiment & High Conviction Investment Ideas - mfd.ru
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growthboerse.de - boerse.de
Aprea taps veteran oncologist as clinical momentum builds for lead cancer drug - MSN
Aprea Therapeutics strengthens global patent portfolio in DNA Damage Response (DDR) cancer therapeutics - marketscreener.com
Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics - TradingView
Aprea Therapeutics Expands Global Patent Portfolio for WEE1 and ATR Programs, Securing Exclusivity Through 2045 - Quiver Quantitative
Aprea Therapeutics Inc (APRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.42%
1.08%
자본화:
|
볼륨(24시간):